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Iron overload coupled with low hepcidin levels are characteristics of hereditary 
haemochromatosis. To understand the role of transferrin receptor (TFR) and intracellular iron 
in hepcidin secretion Chinese hamster ovary transferrin receptor variant (CHO TRVb-1) cells 
were used that express iron-response-element-depleted human TFRC mRNA (TFRC∆IRE). 
Results showed that CHO TRVb-1 cells expressed higher basal levels of cell-surface TFR1 
than HepG2 cells (2.2-fold; p<0.01) and following 5 g/L holotransferrin treatment maintained 
constitutive over-expression at 24 h and 48 h, contrasting the HepG2 cells where the receptor 
levels significantly declined. Despite this, the intracellular iron content was neither higher 
than HepG2 cells nor increased over time under basal or holotransferrin-treated conditions. 
Interestingly, hepcidin secretion in CHO TRVb-1 cells exceeded basal levels at all time-
points (p<0.02) and matched levels in HepG2 cells following treatment. While TFRC mRNA 
expression showed expected elevation (2 h, p<0.03; 4 h; p<0.05), slc40a1 mRNA expression 
was also elevated (2 h, p<0.05; 4 h, p<0.03), unlike the HepG2 cells. In conclusion, the CHO 
TRVb-1 cells prevented cellular iron-overload by elevating slc40a1 expression, thereby 
highlighting its significance in the absence of iron-regulated TFRC mRNA. Furthermore, 
hepcidin response to holotransferrin treatment was similar to HepG2 cells and resembled the 
human response. 
 











Hepcidin is a liver-secreted, 25-mer peptide hormone responsible for maintaining iron 
homeostasis in the body [1]. Systemic iron elevation leads to increased levels of hepcidin that 
binds to ferroportin, the cellular iron-exporter, and induces internalisation and degradation of 
both hepcidin and ferroportin [2]. Thereby, it prevents cellular iron-efflux and regulates 
systemic iron levels. However, the iron-sensing mechanisms that lead to hepcidin secretion 
are unclear. A putative role of transferrin receptor (TFR)1 in modulating hepcidin expression 
was suggested [3] but its significance in transferrin-sensing and hepcidin induction has not 
been sufficiently emphasised. Likewise, even though an involvement of intracellular iron in 
the maturation of prohepcidin into bioactive hepcidin was postulated [4], its function in 
hepcidin peptide secretion has not been sufficiently examined. This is partly because of lack 
of suitable cell lines that could consistently mimic the human hepcidin response to iron 
treatments. Also, majority of previous ex vivo iron supplementation studies and even some 
current investigations focussed on transcriptional regulation of hepcidin [5] and not on 
bioactive hepcidin peptide.  
 
These issues have been addressed in the present study where holotransferrin (holo-Tf) 
induced hepcidin peptide secretion was examined in Chinese hamster ovary transferrin 
receptor variant (CHO TRVb-1) cells. These cells lack endogenous TfR1 and express iron 
response element (IRE)-depleted human TFRC mRNA (TFRC∆IRE) [6]. Due to this unique 
feature it was hypothesised that upon holo-Tf treatment, these cells would bypass the IRE-
dependent TFRC mRNA regulation by iron [7] and show increased iron-uptake. The effect of 
this on hepcidin secretion could be studied and compared with HepG2 cells that possess iron-
regulated TFRC mRNA. Accordingly, after defining the iron saturation of the iron source and 
iron content of the treatment medium, the effect of holo-Tf treatment on cell-surface TFR1, 
intracellular iron content and hepcidin secretion were studied over short and long time-
periods. Furthermore, mRNA expression of CHO-endogenous slc40a1 and human TFRC was 
examined under holo-Tf excess to further understand cellular iron regulation in the absence of 
iron-regulated TFRC. To enable this, the previously unknown sequence of slc40a1 in the 







Materials and Methods  
Cell culture  
Wild type (Wt) CHO and CHO TRVb-1 clone B6, donated by Professor Keith Caldecott 
(University of Sussex, UK) and Dr. Heinz Zoller (University of Innsbruck, Austria), 
respectively, were maintained in Ham’s F12 nutrient mixture (1X) (Invitrogen, UK) with 2 
mM glutamax (Fisher Scientific,UK), 10 % foetal calf serum (FCS) (Biosera, UK) and 1 % 
antibiotic/antimycotic solution (100X) (Fisher Scientific, UK). HepG2 cells (Health 
Protection Agency, UK) were maintained in Eagle’s Minimum Essential Medium (EMEM) 
(Sigma-Aldrich, UK). 
 
Iron treatment studies 
Apo-Tf was iron-loaded using 0.1 M ferric citrate and iron saturation of 5 g/L holo-Tf was 
confirmed by polyacrylamide gel electrophoresis using a 6 M urea gel [8]. Iron concentration 
in holo-Tf treatment medium was determined by ferrozine assay [9]. Cells were seeded at a 
density of 5 X 105 cells in a 6-well plate and maintained until 60 % - 70 % confluent. After 
washing with phosphate buffered saline (PBS) (Invitrogen, UK), cells were treated with 
serum-free EMEM (0 g/L) or 5 g/L holo-Tf from 30 minutes (min) to 24 h and various 
parameters were assessed, as described below.  
 
Detection of human transferrin receptor at mRNA and protein levels in CHO TRVb-1 
cells  
To detect TFRC transcripts in CHO cells, PCRs were conducted with cDNA as template and 
primers listed in the succeeding section. Human TFR1 protein in the CHO TRVb-1 cells was 
confirmed by immunoblotting. Cell pellet was mixed with 2X Laemmli buffer and loaded on 
10 % SDS gels (BIO-RAD, UK.) After electrophoresis, proteins were transferred to a PVDF 
membrane and blocked with 10 % fat-free milk in PBS for 1 h at room temperature (RT). 
Membranes were probed with primary human TFR1 antibody 3B82A1 (Thermo scientific, 
UK) [1:2000] for 1 h at RT and then incubated with a rabbit anti-mouse HRP-conjugated 
secondary antibody (Dako Ltd, UK) [1:1000] for 1 h at RT. Bands were visualised using 
ECL™ Western Blotting Detection Reagents (GE healthcare, UK) on X-ray film. 
 
For analysis of cell-surface TFR1 expression, cells were harvested using TrypLE Express 
(ThermoFisher Scientific, UK), followed by centrifugation for 4 min at 89 x g. Cells were 
suspended in PBC (PBS containing 0.15 % BSA and 1 mM calcium chloride) and transferred 
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to a 96-well plate (2 X 105 cells per well) and centrifuged at 1,260 x g for 30 sec. To each 
well, 20 µL of 16 mg/mL blocking IgG was added. Human transferrin receptor antibody 
(Abcam, UK) [5 µg/mL in PBC)] was added to each test well and PBC was added to the 
control wells. Cells were incubated for 45 min on ice. Following washing, the cells were 
incubated with 10 µg/mL of FITC-labelled secondary antibody STAR9B  rabbit F (ab')2 anti-
mouse IgG (ABD Serotec, UK). After incubation for 30 min on ice, cells were washed with 
PBC again. Cell layer at the bottom of each well was resuspended in 400 µL of PBS and 
TFR1 expression was analysed by  flow cytometry [10].  
 
Determination of intracellular iron content and hepcidin peptide levels and 
mitochondrial activity 
Cellular iron content, as determined by the ferrozine assay [9], was expressed as nmoles of 
iron per mg of protein, as quantified by the Bradford method. The ferrozine assay can detect 
levels from 2 to 300 µM and compares favourably to atomic absorption spectroscopy [9] and 
and ICP-MS [11]. The concentration of hepcidin peptide secreted in the cell media was 
measured as described by Busbridge et.al [12]. Here, using a rabbit anti-human hepcidin 
antibody, plasma hepcidin range from 1.1–55 ng/mL, with a median of 10.8 ng/mL in healthy 
controls, while the limit of detection is 0.6 ng/mL and linearity is up to 200 ng/mL [12]. The 
mitochondrial activity was assessed using the MTT assay [13].  
 
Primer design, cDNA synthesis, sequencing and gene expression analyses  
Primers were designed through software Primer 3 (http://frodo.wi.mit.edu/). Primers 
CCCAGCAGAAGCATTATCTTT (F) and TTCCCATCAATTGGATGTCTT (R) for CHO-
endogenous TfRC and AAAATCCGGTGTAGGCACAG (F) and 
TTAAATGCAGGGACGAAAGG (R) for human TFRC were used to detect TFRC transcripts 
in CHO cells. For gene expression analyses, the primers AAAATCCGGTGTAGGCACAG 
(F) and TTAAATGCAGGGACGAAAGG (R) for human TFRC, 
ATGGGTGCTCACTGTCTGCTA (F) and  GCATTCATATCTGCTAATCTGCTTC (R) for 
CHO-slc40a1, GCTCTTTTCCAGCCTTCCTT (F) and GAGCCAGAGCAGTGATCTCC 
(R) for CHO- beta-actin [14], TGTTTCTGGTAGAGCTCTAT (F) and 
GATATAGCAGGAAGTGAGAA (R)  for human SLC40A1 and 
GCCAAAAGGGTCATCATCTC (F)  and GGTGCTAAGCAGTTGGTGGT (R)  for 
GAPDH [15] were used. RNA was extracted using the TRI reagent (Sigma-Aldrich, UK), 
reverse transcription and cDNA synthesis was performed using QuantiTect reverse 
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transcription kit (Qiagen, UK) and PCRs were performed using Taq PCR master mix (Qiagen, 
UK). All PCR products were sequenced to confirm product identity. Prior to sequencing, 
amplicons were electrophoresed on 1 % agarose gel (Web Scientific, UK) to confirm product 
size and purified using PCR product purification kit (Qiagen, UK). Sequencing was 
conducted at the Wolfson Institute for Biomedical Research (University College London, 
UK). Gene expression was analysed through real-time PCR using Qiagen’s Quantifast SYBR 
green kit in Rotor-gene Q machine (Qiagen, UK) and results were analysed using Rotor-gene 
software series 1.7. Data was expressed as 2-∆∆Ct [16].  
 
Characterisation of slc40a1 sequence in CHO TRVb-1 cells  
DNA was extracted using the isopropanol-ethanol precipitation method [17]. To characterise 
the previously unknown slc40a1 sequence in CHO TRVb-1 cells, genomic similarities 
between related species were assessed (supplementary Table 1) and “PCR walking” was used 
(supplementary information). Characterised CHO-slc40a1 gene sequence was translated to its 
protein sequence (referred as CHO-ferroportin) by using the TRANSLATE tool 
(http://web.expasy.org/translate) and compared with ferroportin sequences of human, mouse 
and rat (supplementary Table 2) by using ClustalW2 (www.ebi.ac.uk). 
 
Bioinformatics analysis of hepcidin peptide sequences 
To assess peptide sequence similarities between human and Chinese hamster, multiple 
sequence alignments were created via CLUSTAL O (1.2.1) available via UniProtKB 
(supplementary Table 2).  
 
Statistical analysis 
Data was analysed by using one-way or two-way ANOVA, accompanied by post-hoc analysis 




Characterisation of CHO TRVb1-cells in basal conditions 
TFR1 expression: Presence of human TFRC mRNA and absence of CHO-
endogenous Tfrc mRNA in CHO TRVb-1 cells was confirmed (Fig.1a). Here, only wt CHO 
cDNA formed product with primers for CHO-endogenous Tfrc (lane 1). As expected, CHO 
TRVb-1 cDNA did not form product with primers for CHO-endogenous Tfrc but formed 
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product with primers for human TFRC (lanes 3 and 4, respectively). Human TFR1 protein in 
the CHO TRVb-1 cells showed expected bands of approximately 180 kDa (lane 1) and 85-90 
kDa (lane 2) under non-reducing and reducing conditions, respectively (Fig.1b), as previously 
observed [18]. Also, the CHO-TRVb1 cells showed significantly higher levels of cell-surface 
TFR1 than HepG2 cells (2.2-fold; p<0.01) (Fig.1c). 
Intracellular iron content and hepcidin secretion: Under basal conditions, CHO 
TRVb-1 cells maintained intracellular iron content over time and did not differ significantly 
from HepG2 cells (Fig.2a). Hepcidin secretion in CHO TRVb-1 cells declined over time from 
30 min to 2 h (p<0.05), followed by substantial reduction at 24 h (3.6-fold; p<0.01), while the 
HepG2 cells showed constant hepcidin levels (Fig.2b). The CHO TRVb-1 cells secreted 
significantly lower levels of hepcidin than HepG2 cells at 2 h (p<0.04) and 24 h (p<0.02). 
 
Iron supplementation studies in CHO TRVb-1 cells  
Analysis of iron saturation of holo-Tf indicated that 90 % of the protein was diferric, with a 
minor proportion of monoferric transferrins (supplementary Fig.2a). Also, iron content in 5 
g/L holo-Tf treatment medium was determined as 105 µM, which was 84 % of the expected 
iron molarity of 125 µM in a 5 g/L holo-Tf preparation (supplementary Fig.2b).  
Cell-surface TFR1 expression: Upon 5 g/L holo-Tf treatment, the CHO TRVb-1 
cells maintained elevated TFR1 expression at 48 h, contrasting the HepG2 cells where TFR1 
levels significantly declined from 24 h to 48 h (p<0.01) (Fig.3).  
Intracellular iron content: Following holo-Tf deprivation (0 g/L), the CHO TRVb-1 
cells neither showed significant variation in intracellular iron content over time nor differed in 
iron content from the HepG2 cells (Fig.4a). Upon holo-Tf treatment (5 g/L), the CHO TRVb-
1 cells showed significantly reduced intracellular iron content from 30 min to 4 h (2.2-fold; 
p<0.01) (Fig.4b). However, the levels significantly increased from 4 h to 24 h (p<0.05) and 
restored iron levels to that observed at earlier time points. Iron levels did not majorly differ 
from the HepG2 cells, except at 4 h (p<0.02) (Fig.4b). 
Hepcidin levels: Holo-Tf deprivation in CHO TRVb-1 cells (Fig.4c) caused a 
significant decline in hepcidin secretion over time from 30 min to 24 h (2.8-fold; p<0.01). The 
levels were similar to HepG2 cells, except at 4 h where the levels in CHO TRVb-1 cells were 
higher than levels in HepG2 cells (1.9-fold; p<0.02). Upon holo-Tf treatment, the CHO-
TRVb-1 cells exceeded basal hepcidin secretion levels at all time-points (p<0.02), but it 
decreased from 30 min to 24 h (1.8-fold; p<0.01), unlike the HepG2 cells that maintained 
constant levels (Fig.4d). Hepcidin levels in CHO TRVb-1 cells were similar to HepG2 cells, 
8 
 
except at 24 h where the CHO TRVb1 cells secreted significantly lower levels than HepG2 
cells (1.7-fold; p<0.02). 
 Gene expression analysis: Holo-Tf deprivation in CHO-TRVb1 cells significantly 
increased TFRC expression at 4 h (3.3-fold; p<0.05) and significantly reduced slc40a1 
expression at 2 h (p<0.03) and 24 h (p<0.05) (Fig.5a). Holo-Tf treatment to CHO TRVb1 
cells significantly increased TFRC expression at 2 h (3.2-fold; p<0.03) and 4 h (5.9-fold; 
p<0.05) (Fig.5b) slc40a1 expression was significantly elevated at 2 h (2.2-fold; p<0.05) and 4 
h (3.4-fold; p<0.03), which followed a substantial decrease at 24 h (p<0.01). In the HepG2 
cells, holo-Tf deprivation caused an insignificant increase in TFRC expression (3.6-fold; 
p=0.09) and a significant decrease in SLC40A1 expression at 24 h (p<0.03) (Fig.5c). 
Following holo-Tf treatment, TFRC expression significantly increased at 2 h (3-fold; p<0.01) 
whereas SLC40A1 expression significantly decreased at 4 h (p<0.05) (Fig.5d).  
Mitochondrial activity: The CHO TRVb1 and HepG2 cells did not show any major 
change in mitochondrial activity under holo-Tf deprived and supplemented conditions (Fig.6). 
 
Characterisation of slc40a1 in CHO TRVb1-cells  
To enable gene expression analyses, the previously unknown sequence of CHO-endogenous 
slc40a1 was partially characterised (Fig.7). These characterised sequences displayed very 
high percentage similarities with corresponding slc40a1 sequences in human (>88%), mouse 
(>90%) and rat (>90%) (Fig.7b). Partial alignment of the sequence is shown in supplementary 
Fig.1. The characterised CHO-slc40a1 sequence was translated into a protein sequence and 
compared with ferroportin sequences in other species. Data showed conservation of many 
functionally significant domains in the proposed transmembrane region and the hepcidin 
binding region in ferroportin (Fig.7c). Particularly conserved were N144 and V162, which if 
mutated, exhibit hepcidin insensitivity. The position of C326 in relation to other amino acids 
is also conserved in the proposed hepcidin binding region, lying outside the transmembrane 
region and therefore appears to be consistent with its role in binding to hepcidin. K253, Y302 
and Y303, which are involved in ferroportin internalisation and degradation upon hepcidin 
binding are conserved in this characterised CHO-slc40a1 sequence and are located in the 
same position relative to other amino acids as in human, mouse and rat ferroportin [19]. Also, 
cysteines which form disulphide bonds and usually play a significant role in the folding and 





Bioinformatics analysis of hepcidin  
Peptide sequence similarities between hamster and other species were assessed. The two 
predicted hepcidin isoforms in Chinese hamster [21] bear 84 % sequence similarity with each 
other (Fig.8a) and the terminal 25-mer region bears 84 % sequence similarity with human 
hepcidin-25 (Fig.8b). Specifically, the first eleven amino acids at its N-terminus are identical 
to corresponding positions in human hepcidin-25, except that threonine at position 2 in human 
hepcidin-25 is replaced by serine, which has a side chain similar to threonine. Moreover, there 




Here, the effect of excess holo-Tf on intracellular iron levels and hepcidin secretion was 
examined in the CHO TRVb-1 cells that possess iron-unregulated TFRC mRNA (TFRC∆IRE) 
[6] and compared with the HepG2 cells that possess iron-regulated human TFRC mRNA. A 
high concentration of 5 g/L holo-Tf was chosen to promote intracellular iron overload as 
previous holo-Tf supplementation studies at 2.5 g/L holo-Tf showed no effect on hepcidin 
mRNA [23] and 30 µM holo-Tf (1.2 g/L) gave conflicting results with either up regulation 
[24] or down regulation of hepcidin mRNA [25]. On the other hand, when 100 µM holo-Tf 
(approximately 4 g/L) was used for treatment, an increase in hepcidin mRNA expression was 
observed [26].  It is also important to note that non-Tf bound iron (NTBI) may play a role in 
iron uptake. However, pathways for NTBI uptake are less clearly defined compared to TBI 
uptake. In addition, several previous studies with NTBI showed no effect [1, 24] or even 
down regulation [15, 25, 27] of hepcidin mRNA. Moreover, the holo-Tf treatment medium 
was prepared in serum-free Eagle’s Minimal Essential Medium (EMEM) that is deprived of 
inorganic iron sources. This was confirmed by the ferrozine assay, which showed no 
detectable iron levels in this medium, denoted as 0 g/L (supplementary Fig. 2b), while it 
showed approximately 6 µM in a FCS (10%)-supplemented EMEM. Thus, the current 
findings are only based on holo-Tf treatment. 
 
Cellular iron regulation and characterisation of hepcidin response  
Human TFRC at mRNA and protein levels were confirmed in CHO TRVb-1 cells (Fig.1a and 
1b). The cells expressed 2.2-fold higher basal levels of cell-surface TFR1 than HepG2 cells 
(Fig.1c). Following 5 g/L holo-Tf treatment, the HepG2 cells significantly decreased cell–
surface TFR1 expression over time (Fig.3c) and demonstrated an expected iron-regulated 
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response where TFRC transcripts are sensitive to intracellular iron sufficiency due to the IRE 
region [7] and subsequently decrease cell-surface TFR1 to avoid further iron-uptake, as 
confirmed here. Contrastingly, the CHO TRVb-1 cells showed constantly elevated expression 
despite prolonged extracellular holo-Tf excess; a dysregulated characteristic of cell-surface 
TFR1 in these cells demonstrated in this study for the first time (Fig.3c). This dysregulation 
due to TFRC∆IRE was also reflected at mRNA level where despite excess extracellular holo-
Tf, TFRC mRNA expression significantly increased at 2 h and 4 h (Fig.5b).  
 
Although the constitutively high expression of cell-surface TFR1 (Fig.3c) and TFRC∆IRE 
together indicated a potential for increased iron-uptake, surprisingly, the CHO TRVb-1 cells 
neither showed higher intracellular iron levels than HepG2 cells under basal conditions 
(Fig.2a) nor majorly increased iron-uptake upon holo-Tf supplementation (Fig.4b), contrary 
to the expected. This could be attributed to the elevated slc40a1 expression, as observed at 2 h 
of holo-Tf treatment to promote cellular iron-efflux [28] and circumvent any potential 
increase in iron content caused by increased TFRC mRNA expression at the same time 
(Fig.5b). Accordingly, at 4 h of holo-Tf treatment, a 3.2-fold increase in slc40a1 expression 
corresponded to a 2.2-fold decrease in intracellular iron content (Fig.5b and Fig.4b). Such 
elevations in slc40a1 expression are consistent with the iron-sensitive feature of the IRE 
region on slc40a1 mRNA [29]. This feature prevented cellular iron overload in CHO TRVb-1 
cells and did not allow iron levels to exceed beyond that in HepG2 cells, which showed 
constant levels of SLC40A1 mRNA expression (Fig.5d). 
Interestingly, the CHO TRVb-1 cells are similar to cancer cells that also over-express 
cell-surface TFR1 to acquire iron for cell survival, growth and proliferation [30]. However, 
while the human breast cancer cells showed reduced ferroportin expression compared to non-
malignant cells [31], presumably to retain intracellular iron, the CHO TRVb-1 cells differed 
and showed elevated slc40a1 expression, aiming for iron-efflux (Fig.5). Thus, unlike cancer 
cells, the CHO-TRVb1 cells exhibited a fascinating regulatory phenomenon where scl40a1 
maintained intracellular iron-homeostasis in presence of excess extracellular holo-Tf and 
abundant cell-surface TFR1, while TFRC mRNA was incapable of contributing to 
intracellular iron-sensing due to TFRC∆IRE. The overall aim of protecting the cells from 
excess-iron-mediated toxicity was achieved, as confirmed through the MTT assay, which 




Here, we presented novel data where the CHO TRVb-1 cells secreted hepcidin under basal 
conditions; and following holo-Tf treatment, exceeded basal levels at all time-points (Fig.2b 
and Fig.4d). This resembled the human response to excess systemic iron levels [1] and 
suggested that these cells were suitable to study holo-Tf-induced hepcidin responses. The 
antibody utilised detects the N-terminal 14 amino acid region of human hepcidin-25 [12], 
(Fig. 8b, amino acids in bold). Here, 12 out of the total 14 amino acids are identical to the 
corresponding region in hamster hepcidin (Fig. 8b, highlighted grey). Moreover, in position-2 
of human hepcidin-25, threonine in human is replaced by a structurally and functionally 
similar amino acid serine in hamster. This leaves only one dissimilar amino acid at position 
12. Such high level of similarity in the antibody binding region of hepcidin-25 fully supports 
the successful detection of hamster hepcidin by this method. The method used here has also 
been successfully used to detect hepcidin in rhesus monkeys [32].  
 
Under basal conditions, the CHO TRVb-1 cells secreted significantly lower levels of hepcidin 
than HepG2 cells (Fig.2b). Since HepG2 cells are of hepatic origin whereas CHO TRVb-1 
cells are ovary-derived, this data is consistence with the tissue–specific nature of hepcidin, 
where, in human and animals, hepcidin is predominantly secreted by liver hepatocytes with 
lower amounts being secreted by other tissues [33], however the peptide expression level has 
been reported higher in rat kidney than human kidney by immunoblot analysis (Kulaksiz et 
al., 2005). Also, overexpressed TFR1 expression on the cell-surface may have disturbed its 
physiological ratio with HFE and TFR2, the hepcidin inducing proteins [34], thereby causing 
lower hepcidin secretion under basal conditions. However, upon holo-Tf treatment, hepcidin 
levels in CHO TRVb-1 cells matched the levels in HepG2 cells, at least up to 4 h (Fig.4d), 
which indicated that tissue-specificity was overruled and hepcidin response to holo-Tf 
treatment governed. This may have occurred via two mechanisms; first, upon binding of holo-
Tf to TFR1, the TFR1-bound HFE may be displaced and free to bind to TFR2 to induce 
hepcidin [3] and second, due to the predominance of response–specific factors over tissue-
specific factors [35]. Since, the expected intracellular iron overload was not achieved, exactly 







Characterisation of CHO-slc40a1 and bioinformatics study of hepcidin peptide 
sequences 
In order to study iron-efflux in CHO TRVb-1 cells and cellular iron regulation via real-time 
PCR, genomic similarities between species were examined (supplementary Table 1) and 
partial characterisation of the previously unknown slc40a1 sequence in CHO TRVb-1 cells 
was achieved (Fig.7a and 7b). As expected, the characterised slc40a1 sequences in CHO 
TRVb-1 cells bore more than 88 % sequence similarities with the corresponding sequences of 
human, mouse and rat (Table 1) and were subsequently used to design primers for gene 
expression analysis  (Supplementary Fig.1, Fig.5a and 5b). Comparison of the characterised 
and then translated CHO-slco40a1 sequence with ferroportin sequences from other species 
showed an overall 92 % similarity. Several amino acids in the functionally significant 
domains such as the proposed transmembrane region and hepcidin binding region are 
conserved, as presented here for the first time (Fig.7c). Overall, the data indicates that the 
sequence of ferroportin is well conserved amongst species. 
 The two hepcidin isoforms of Chinese hamster [21] show high sequence similarity 
with human hepcidin-25 (Fig.8b). This is particularly in the N-terminal region that is 
important for its interaction with ferroportin, the furin cleavage site on prohepcidin that 
releases bioactive hepcidin and the 8 cysteine residues, which are believed to have structural 
and functional significance [22].  
 
Conclusion  
Despite the substantially higher levels of cell-surface TFR1, intracellular iron overload was 
not achieved in CHO TRVb-1 cells, possibly due to elevated slc40a1 expression. This 
demonstrated the importance of the iron–efflux protein ferroportin in maintaining intracellular 
iron homeostasis in the absence of iron-regulated TFRC mRNA. Furthermore, we have 
demonstrated novel data whereby CHO-endogenous hepcidin secretion occurred under basal 
conditions and was further stimulated upon 5 g/L holo-Tf stimulus, resembling the human 
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Abbreviations:  
CHO       Chinese hamster ovary  
EMEM    Eagle’s minimal essential medium 
H             Hours 
IRE          Iron responsive element 
IRP          Iron regulatory protein  
Min         minutes 
MTT        3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
PCR        Polymerase chain reaction 
Sec          Seconds 
Slc40a1   Gene encoding the iron-exporter protein ferroportin 
Tf            Transferrin 
TFR         Transferrin receptor 












































































































Figure captions   
Fig.1 TFRC transcripts and protein in CHO-TRVb-1 cells 
Fig.2 Iron and hepcidin levels in CHO TRVb-1 cells under basal conditions  
Fig.3 Cell-surface TFR1 in CHO-TRVb-1 cells following iron treatment  
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Fig.4 Iron and hepcidin levels in CHO TRVb-1 cells following iron treatment 
Fig.5 mRNA expression of human TFRC and endogenous slc40a1 in CHO TRVb-1 cells 
Fig.6 Mitochondrial activity in CHO TRVb-1 cells following iron treatment  
Fig.7 Characterisation of slc40a1 in CHO TRVb-1 cells 








Figure Legends  
 
Fig.1 TFRC transcripts and TFR1 protein in CHO TRVb-1 cells   
(a): The cDNA from CHO TRVb-1 and Wt CHO cells was amplified and run on 1 % agarose 
gel. Lane 1= Amplicon of Wt CHO cDNA obtained by using CHO-endogenous TfRC 
primers; expected product-size is 230 bp; lane 2= PCR of Wt CHO cDNA with human TFRC 
primers; no product expected; lane 3= PCR of CHO TRVb-1 cDNA with CHO-endogenous 
TfRC primers; no product expected; lane 4= Amplicon of CHO TRVb-1 cDNA obtained by 
using human TFRC primers; expected product size is 179 bp. 
(b): Cell pellet of CHO TRVb-1 cells was probed with human TFR1 antibody and Western 
blot detected human TFR1 protein in CHO TRVb-1 cells. Lane 1= CHO TRVb-1 cells in non-
reducing conditions; lane 2= CHO TRVb-1 cells in reducing conditions.  
(c): Cell-surface TFR1 levels in CHO TRVb-1 cells and HepG2 cells were assessed. Data is 
presented as mean ± SEM (n=3). *p<0.01 compared to HepG2 cells (1-way ANOVA). 
 
Fig.2 Basal levels of iron and hepcidin peptide secretion in CHO TRVb-1 cells  
Intracellular iron levels (a) and hepcidin secretion (b) in CHO TRVb-1 cells were measured 
by using the ferrozine assay and radioimmunoassay, respectively, under basal conditions. 
Data is presented as mean ± SEM (n=3). *p<0.05 and **p<0.01 compared to 30 min in CHO 
TRVb-1 cells; #p<0.04 and ##p<0.02 compared to HepG2 cells at 30 min and 24 h, 
respectively (2-way ANOVA). Analysis showed significant differences between cell-types 
(p=0.019) and for cell-type x time (p=0.039) (post-hoc analysis by Tukey’s method) 
 
Fig. 3 Effect of iron supplementation on cell-surface expression of TFR1 in CHO TRVb-
1 cells  
CHO TRVb-1 and HepG2 cells were treated with 5 g/L holo-Tf and cell-surface TFR1 was 
assessed by flow cytometry. Representative images of CHO TRVb-1 cells following 
treatment for 24 h and 48 h are depicted in ‘a’ and ‘b’, respectively. Data is presented as mean 
± SEM (n=3). *p <0.01 compared to 24 hours in HepG2 cells (1-way ANOVA). 
 
Fig.4 Effect of iron supplementation on intracellular iron levels and hepcidin secretion 
in CHO TRVb-1 cells 
Intracellular iron levels (a & b) and hepcidin secretion (c & d) in CHO TRVb-1 cells were 
measured by using the ferrozine assay and radioimmunoassay, respectively. Data is presented 
18 
 
as mean ± SEM (n=3). *p<0.01 compared to 30 min in CHO TRVb-1 cells; #p<0.02 
compared to HepG2 cells at the corresponding time-point; ^p<0.05 compared to 4 h in CHO 
TRVb-1 cells (1-way ANOVA). 
 
Fig.5 Gene expression studies in CHO TRVb-1 and HepG2 cells 
mRNA expression levels of human TFRC and endogenous slc40a1 in CHO TRVb-1 cells 
upon holo-Tf deprivation (0 g/L) (a) and holo-Tf supplementation (b) are shown. Also, the 
effect of holo-Tf deprivation (c) and holo-Tf supplementation (d) in HepG2 cells has been 
shown. Data is presented as mean ± SEM (n=3). *p<0.05, **p<0.03 compared to 30 min; 
#p<0.01 compared to 4 h (1-way ANOVA).  
 
Fig.6 Effect of iron supplementation on mitochondrial activity in CHO TRVb-1 cells  
CHO TRVb-1 and HepG2 cells were treated with 0 g/L (a) and 5 g/L (b) holo-Tf and 
mitochondrial activity in the cells was determined by using the MTT assay. Data is presented 
as mean ± SEM (n=3). 
 
Fig.7 Characterisation of CHO-endogenous slc40a1  
(a): Amplicons of slc40a1 in CHO TRVb-1 cells and rodents with primers (F1) and (R1) in 
the first round of sequencing have been shown. Here, lane 1= rat liver DNA (control), lane 2= 
mouse kidney cDNA (control), expected sizes of controls were 160 bp. Lane 3= CHO TRVb-
1 DNA, Lane 4= negative control. Encircled product in lane 3 was purified and its sequence 
identity was confirmed as described in the methods section. 
(b): The table shows percentage sequence similarities between the characterised CHO-slc40a1 
sequences and slc40a1 sequences of related species.  
(c): The alignment underpins functional study of the characterised CHO- slc40a1 sequence. 
The characterised sequence was translated using the functional tool “TRANSLATE” available 
at web.expasy.org, and compared with ferroportin sequences of different species. 
Key to alignment: 
 Proposed transmembrane region  
 Proposed hepcidin binding domain  
 K253,Y302,Y303: amino acids affecting ferroportin degradation and internalisation  
 N144H, V162 ∆: Mutations that disruption ferroportin function 
 * represents conserved amino acid between species 
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Fig.8 Conservation of hepcidin sequence amongst species 
Conservation of amino acids between the predicted preprohepcidin sequences in Chinese 
hamster (Cricetulus griseus) (a) and between hepcidin isoforms in hamster and hepcidin in 
human (b) are shown. Downward arrow shows the cleavage-site of furin convertase, which 












Figure 1  
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Figure 6  
 































































































Human      MTRAGDHNRQRGCCGSLADYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNSLLL 60 
Mouse      ------------------------------------------------------------ 
Rat        MTKSRDQTHQEGCCGSLANYLTSAKFLLYLGHSLSTWGDRMWHFAVSVFLVELYGNGLLL 60 
Hamster    --------------------------------------------------------SLLL 4 
                                                                                 
Human      TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKHEL 120 
Mouse      TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKNEL 60 
Rat        TAVYGLVVAGSVLVLGAIIGDWVDKNARLKVAQTSLVVQNVSVILCGIILMMVFLHKNEL 120 
Hamster    TAVYGLVVAGSVLVA-----------------QTSLVVQNVSVILCGIILMMVFLHKNEL 47 
           **************                  *************************:** 
 
Human      LTMYHGWVLTSCYILIITIANIANLASTATAITIQRDWIVVVAGEDRSKLANMNATIRRI 180 
Mouse      LTMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 120 
Rat        LNMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 180 
Hamster    LTMYHGWVLTVCYILIITIANIANLASTATAITIQRDWIVVVAGENRSRLADMNATIRRI 107 
           *.******** **********************************:**:**:******** 
                                N144H             V162∆  
          
Human      DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYVLLWKVYQKTPALAVKAGLK 240 
Mouse      DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAALK 180 
Rat        DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAALK 240 
Hamster    DQLTNILAPMAVGQIMTFGSPVIGCGFISGWNLVSMCVEYFLLWKVYQKTPALAVKAVLK 167 
           ****************************************.**************** ** 
 
 
Human      EEETELKQLNLHKDTEPKPLEGTHLMGVKDSNIHELEHEQEPTCASQMAEPFRTFRDGWV 300 
Mouse      VEESELKQLTSPKDTEPKPLEGTHLMGEKDSNIRELECEQEPTCASQMAEPFRTFRDGWV 240 
Rat        VEESELKQLTSPKDTEPKPLEGTHLMGEKDSNIRELECEQEPTCASQIAEPFRTFRDGWV 300 
Hamster    VEEAELKQLNLPKDTEPKSLEGTHLMGEKDSNIRELEHEQESTCASQIAEPFRTFRDGWV 227 
           **:*****.  ******.******** *****:*** ***.*****:************ 
                      K253 
 
Human      SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAF 360 
Mouse      SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSILMGASAITGIMGTVAF 300 
Rat        SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLSGSILSVLMGASAITGIMGTVAF 360 
Hamster    SYYNQPVFLAGMGLAFLYMTVLGFDCITTGYAYTQGLS---------------------- 265 
           **************************************                       










Human 92 % 89 % 
Mouse 92 % 93 % 






Hamster Hepc-1 MAQSTKIQAACLLLLLIAPQLLRAATEGTRVRQPEALQPQHRTADQTDRTDRTLLIPKRT  
Hamster Hepc 2 MAQSTKIQAACLLLLLIASLA-SSTLLQQLVRQPEALQPQHRTKAQTDRTDRTLLIPKRT  
               ******************     ::     *************  *************** 
 
 
Hamster Hepc-1 KRDSHFPICIFCCYCCGNFKCGVCCKT 87 
Hamster Hepc-2 KRDSHFPICIFCCYCCGNFKCGVCCKT 86 





Hamster Hepc-1 KRDSHFPICIFCCYCCGNFKCGVCCKT  
Hamster Hepc 2 KRDSHFPICIFCCYCCGNFKCGVCCKT  
Human Hepc     RRDTHFPICIFCCGCCHRSKCGMCCKT  
               :**:********* ** . ***:**** 
                                                        
 
 
 
 
 
Furin convertase cleavage site   Position 2   Position 12  
